FDA Submission Expected This Summer - Invest Before It Happens

This company is making heart disease easier to detect with AI. Their tech has officially been designated a "Breakthrough" by the FDA. You now have an opportunity to get in at a potential inflection point.

Pfizer Seeks Label Expansion For Hemophilia Drug After Promising Data

Vandana Singh
June 26, 2025

Pfizer Inc. (NYSE:PFE) released topline results from the Phase 3 BASIS study evaluating Hympavzi (marstacimab) for adults and adolescents living with hemophilia A or B with inhibitors.

Phase 3 BASIS study in patients without inhibitors supported the FDA approval of Hympavzi in October 2024.

The study met the primary endpoint and key secondary bleeding endpoints, demonstrating the superiority of once-weekly subcutaneous Hympavzi in improving key bleeding outcomes compared to on-demand treatment in a patient population where less burdensome treatment approaches are needed.

Also Read: FDA Approves Sanofi’s Hemophilia Drug

The BASIS trial demonstrated that prophylactic treatment with Hympavzi resulted in a statistically significant and clinically relevant reduction in annualized bleeding rate (ABR) of treated bleeds in people with severe hemophilia A or B with inhibitors.

Forty-eight people living with hemophilia were treated with Hympavzi during 12 months versus an on-demand intravenous regimen with bypassing agents, administered as part of usual care in the six-month lead-in period.

Hympavzi was superior to on-demand treatment with a 93% reduction in ABR over 12 months (ABR 1.39 vs ABR on-demand 19.78; p < 0.0001).

The superiority of Hympavzi was also demonstrated across all bleeding-related secondary endpoints, spontaneous bleeds, joint bleeds, target joint bleeds, and total bleeds, Pfizer announced on Thursday.

Hympavzi was generally well-tolerated, consistent with the non-inhibitor cohort of the BASIS study and Phase 1/2 results. No deaths or thromboembolic events were reported.

Analyses of the full Phase 3 dataset from the inhibitor cohort of the BASIS study are ongoing, and additional data will be presented at upcoming medical meetings.

Hympavzi’s mechanism of action is differentiated from those of FVIII and FIX replacement treatments. Instead of replacing missing or insufficient clotting factors, Hympavzi is intentionally designed to target tissue factor pathway inhibitor (TFPI), one of the body’s natural mechanisms that inhibits the initiation of blood clotting.

By targeting the Kunitz 2 domain of TFPI, Hympavzi may help re-establish balance between bleeding and blood clot formation. Its goal is to offer a combination of bleed protection, good tolerability, and straightforward administration.

Pfizer plans to discuss these data with regulatory authorities to initiate regulatory filings for Hympavzi for hemophilia patients with inhibitors.

Price Action: PFE stock is trading lower by 0.05% to $24.25 at last check Thursday

Read Next:

  • RFK Jr. Overhauls CDC Vaccine Panel, Sparking Expert Backlash, Boycott From Top Medical Group

Photo by ShU studio via Shutterstock

Continue Reading...

Popular

More Americans Ditch Checking And Savings Account For These Higher-Yield Alternatives Amid Economic Jitters

More and more Americans are choosing to move their funds from traditional checking and savings accounts to investment income vehicles. This trend highlights the resilience of the U.S. economy in the face of high inflation and tariff-related uncertainty.

U.S. Military Flagged This Metal as Critical-Here's Why That Matters Now - Ad

Antimony is back on the Pentagon's radar, and America is scrambling for domestic supply. Early Investors are looking to ride the next strategic metals wave.

Stellantis warns of $2.7 billion loss for 1st half of 2025 due to tariffs and some big charges

Stellantis, the maker of Jeep and Ram vehicles, says its preliminary estimates show a 2.3 billion euros ($2.68 billion) net loss in the first half of the year due to U.S. tariffs and some hefty charges.

Jim Cramer Made 'FAANG' Popular, Now He Says There's A New Acronym To Describe These Retail Favorite Stocks — 'PARC'

Renowned TV host Jim Cramer is stirring chatter on X with another buzzworthy "meme stock" acronym, aimed at a new group of retail-favorite stocks that are defying gravity.

Leaked Memo Points to $100 Trillion Wealth Transfer Starting Soon - Ad

The U.S. Department of the Interior's internal memo has leaked ... and the contents are shocking. A federally backed resource monetization plan may soon go live, and it could trigger a new gold rush into select energy and mineral stocks. Investing legend Whitney Tilson breaks it all down inside.

Palantir's AI Is Going Physical - Ad

The next wave of security AI is happening now. Palantir just joined forces with a company already doing the work.

Trump Hit With Backlash Over Use of Antisemitic Slur at Iowa Rally

President Trump faced criticism from Jewish leaders and lawmakers on Friday after using a term historically associated with antisemitic stereotypes.

The Tesla Shock Nobody Sees Coming - Ad

While headlines scream "Tesla is doomed"...Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as July 23rd.

Palantir Makes a Move - Now Look At the Chart - Ad

One under-the-radar company just partnered with Palantir to take autonomous security to the next level.

President Trump announces trade deal with Vietnam that will let US goods into the country duty-free

WASHINGTON (AP) — President Donald Trump announced a trade deal with Vietnam Wednesday that would allow U.S. goods to enter the country duty-free.

Del Monte, the 139-year-old canned fruits and vegetables company, seeks bankruptcy protection

Del Monte Foods, the 139-year-old company best known for its canned fruits and vegetables, is filing for bankruptcy protection as U.S. consumers increasingly bypass its products for healthier or cheaper options.

Back This Medical AI Tech - Ad

You don't often find healthcare tech company valued at $4M. HeartSciences is an exception. With $75M invested, including R&D, clinical trials, and product development, their patented AI software is approaching FDA submission, a potential major inflection point.

Trump Says 5 Jets Downed During India-Pakistan Conflict: '...Shot Out Of The Air'

President Donald Trump during a dinner with Republican lawmakers stated, that up to 5 jets were shot down during the India-Pakistan conflict.

This WWII Metal Is Quietly Powering America's Next Defense Build-up - Ad

Used in armor, ammo, and batteries... antimony helped win World War II. Now, with China tightening control, one company may have found a new domestic source-just in time.

Tesla's Cybertruck Struggles, Uber's Autonomous Drive And More: This Week In Mobility

Tesla faced declining Cybertruck demand and sluggish U.S. sales, while Uber made bold moves into autonomous driving.

Is KBR About To Land An $8 Billion Indonesia Deal?

Indonesian Economic Minister announced plans for $8 billion refinery contract with KBR Inc., part of broader trade deal with US. $34 billion in potential deals.

How to Hack a $1.3T Market - Ad

Forget concrete. The new foundation for real estate success is digital, and Pacaso leads the way. Their tech unlocks a $1.3T real estate market. They've already earned $110M+ in gross profits in their operating history and reserved the Nasdaq ticker PCSO.

Boeing Wins $2.8 Billion US Space Force Contract To Build Nuclear-Resilient Satellites For Strategic Communications

The Boeing Co. has secured a $2.8 billion contract from the U.S. Space Force to develop and produce strategic satellite communications systems, marking a significant win for the aerospace giant's defense portfolio.

This WWII-Era Mine Could Fast-Track a Critical Metal Comeback-and Investor Interest - Ad

This critical metal powered the Allied WWII effort-and now it's needed again for defense.. One overlooked firm just revived a historic mine with existing infrastructure, giving it a potential head start.

Faced with geopolitics and trade war, US companies in China report record-low new investment plans

WASHINGTON (AP) — American companies in China are reporting record-low new investment plans for this year and declining confidence in profits, while uncertainty in U.S.-China relations and President Donald Trump’s tariffs have become their top concerns, according to a business survey released Wednesday.

Trump’s pivot from aid to trade leaves Africa wary as it faces tariffs and uncertainty

HARARE, Zimbabwe (AP) — When U.S. President Donald Trump met five African leaders in Washington in July, his lack of familiarity with the continent was on display. He — Liberia’s official language — and gestured at another leader to wrap up remarks. But the bigger takeaway was Trump’s pledge to transform U.S.-Africa relations: a shift from aid to trade, even as the region reels from steep tariffs and sweeping aid cuts.

FDA Submission Expected This Summer - Invest Before It Happens - Ad

This company is making heart disease easier to detect with AI. Their tech has officially been designated a "Breakthrough" by the FDA. You now have an opportunity to get in at a potential inflection point.

Leaders of the UK and Germany to sign a treaty on defense, trade and migration

LONDON (AP) — and are set to sign a treaty on Thursday pledging to tighten defense ties and step up law-enforcement cooperation against gangs that smuggle migrants .

Democratic Congressman Tom Suozzi's Stock Sale Used A Disclosure Loophole: Report

Rep. Suozzi under scrutiny for $50,000 stock sale without disclosure. Congress now addressing loophole in law.

U.S. Military Flagged This Metal as Critical-Here's Why That Matters Now - Ad

Antimony is back on the Pentagon's radar, and America is scrambling for domestic supply. Early Investors are looking to ride the next strategic metals wave.

Elon Musk Changed His Number, Became Unreachable After Trump Feud, Reveals Speaker Mike Johnson: 'I Sent Him A Long Text Message, And Then...'

Tesla Inc. (NASDAQ: TSLA) CEO Elon Musk has reportedly changed his phone number following a fued with President Donald Trump and disagreement with Speaker Mike Johnson over the Republican's tax-and-spending bill.

Leaked Memo Points to $100 Trillion Wealth Transfer Starting Soon - Ad

The U.S. Department of the Interior's internal memo has leaked ... and the contents are shocking. A federally backed resource monetization plan may soon go live, and it could trigger a new gold rush into select energy and mineral stocks. Investing legend Whitney Tilson breaks it all down inside.

Trump appointees pushed more marble in Fed building renovation White House now attacks

WASHINGTON (AP) — President Donald Trump has looked to the marble finishes and hefty price tag of the Federal Reserve headquarters to to fire Chair Jerome Powell, with whom he has tussled for years over interest rates. But the extensive use of marble in the building is, at least in part, the result of policies backed by Trump himself.

Mark Cuban Praised His 'Hustling' Son, But Told Kids: 'Figure Out Who You Are, You Don't Need To Follow In My Footsteps'

Jake Cuban embarked on an entrepreneurial journey reminiscent of his father's early business ventures by starting a side hustle selling candy at his school.

Palantir's AI Is Going Physical - Ad

The next wave of security AI is happening now. Palantir just joined forces with a company already doing the work.

How Trump could use a building renovation to oust the Fed chair

WASHINGTON (AP) — President says he has finally found a way to achieve his goal of removing Federal Reserve Chair Jerome Powell, accusing him of mismanaging the U.S. central bank’s $2.5 billion renovation project.

Trending Now

Information, charts or examples are for illustration and educational purposes only and not for individualized investment management This message contains commercial elements, such as advertising. We only send these offers to those who have opted in to our newsletter. Past performance is not indicative of future results. For these reasons we strongly suggest trading in a DEMO/Simulated account. The information provided by us is for educational and informational purposes only. We make no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended and have not determined if the statements and opinions of the advertiser are accurate, correct or truthful. If you use, act upon or make decisions in reliance on information contained or any external source linked within it, you do so at your own peril and agree to hold us, our officers, directors, shareholders, affiliates and agents without fault.

Copyright trendadvisor.net
Privacy Policy | Terms of Service